Impact of DPYD Genetic Variant on Colorectal Cancer Treatment
Author Information
Author(s): De Mattia Elena, Polesel Jerry, Scarabel Lucia, Cecchin Erika
Primary Institution: Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
Hypothesis
The study aims to elucidate the clinical role of the DPYD rs4294451 variant as predictive pharmacogenetic markers of the clinical outcome related to fluoropyrimidine-based treatment in colorectal cancer patients.
Conclusion
Carriers of the DPYD rs4294451-T allele have a lower risk of severe toxicity from fluoropyrimidine treatment but a shorter overall survival.
Supporting Evidence
- Carriers of the DPYD rs4294451-T allele had a lower risk of developing severe toxicity.
- Patients with the T allele experienced a longer time to severe toxicity development.
- Overall survival was shorter for patients with the T allele compared to those with the AA genotype.
Takeaway
Some people have a gene that helps them handle cancer treatment better, but it might also mean they don't live as long.
Methodology
The study analyzed clinical data and biological samples from colorectal cancer patients treated with fluoropyrimidines, focusing on the DPYD rs4294451 variant.
Limitations
The study could not analyze the clinical impact of haplotype combinations due to insufficient sample size.
Participant Demographics
{"gender_distribution":{"female":250,"male":395},"age_distribution":{"<55":145,"55-64":210,"65-69":131,"≥70":157}}
Statistical Information
P-Value
0.0406
Confidence Interval
{"hematological":"0.15–0.98","any_type":"0.22–0.88"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website